证券代码：000935 证券简称：四川双马 公告编号：2025-10 二、经营业绩和财务状况情况说明 报告期内，公司业绩较上年同期有所下降，主要原因如下：一是受资本市场波 动影响，公司参投基金所投资项目公允价值出现波动。上年同期，基金投资项目整 体取得了良好的收益，而本报告期未能实现持续增长。二是公司建材业务所在区域 前三季度市场需求恢复缓慢，尽管第四季度在国家稳定房地产市场等政策支持下， 市场需求有所回升，但全年整体销售量及价格仍较上年同期出现明显下滑。 面对业绩下滑，公司积极采取多项措施，通过优化运营效率、业务拓展、加强 成本管控等方式，努力创造收益。一方面，公司持续推进宜宾和谐绿色产业发展股 权投资合伙企业（有限合伙）的募集工作，有效增加了管理费收入；另一方面，通 过寻找替代原燃材料、严格控制现金流等方式，降低了生产成本，部分缓解了业绩 下降的压力。此外，公司通过收购深圳市健元医药科技有限公司实现了业务突破， 为公司未来的发展奠定了坚实基础。 四川和谐双马股份有限公司 2024年度业绩快报 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示：本公告 ...

2025年一季度业绩预告 证券代码：000935 证券简称：四川双马 公告编号：2025-11 四川和谐双马股份有限公司 预计的经营业绩: □扭亏为盈 √同向上升 □同向下降 | 项目 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市公司 股东的净利润 | 盈利：10,000万元–14,000万元 | 盈利：872万元 | | | 比上年同期增长：1,047% - 1,506% | | | 扣除非经常性损 益后的净利润 | 盈利：9,500万元–13,500万元 | 亏损：421万元 | | | N/A | | | 基本每股收益 | 盈利：0.13元/股– 0.18元/股 | 盈利：0.01元/股 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、本期业绩预计情况 （一）业绩预告期间 2025年1月1日-2025年3月31日 （二）业绩预告情况 注：截至2025年3月31日，公司总股本为763,440,333股，回购专用证券账户中的股份为6,219,875股。 根据《深圳证券交易所上市公司自律监管指引第9号——回购股 ...

证券代码：000935 证券简称：四川双马 公告编号：2025-9 四川和谐双马股份有限公司 关于控股股东所持部分股份质押展期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四川和谐双马股份有限公司(简称"公司"）于近日接到控股股东北京和谐 恒源科技有限公司（简称"和谐恒源"）的告知函，获悉和谐恒源对所持有的本 公司的部分股份办理了质押展期业务，具体事项如下： 上述"占其所持股份比例"为该笔质押股份的数量占和谐恒源及其一致行动 人持股数量的比例。所质押的股份未负担重大资产重组等业绩补偿义务。 上述股份的原质押情况详见公司于2024年4月24日及2024年4月26日披露的 《关于控股股东所持部分股份解除质押及再质押的公告》和《关于控股股东所持 部分股份解除质押及再质押的公告》。依据和谐恒源出具的告知函，和谐恒源对 所持有的本公司的部分股份办理质押展期的主要原因为偿还债务，就质押事项和 谐恒源具备履约偿债能力，所质押的股份不存在平仓风险，对上市公司的生产经 营及公司治理等不会产生影响，和谐恒源已采取相关防范应对措施。 二、股东股份累计被质押的情况 股 东 ...

证券代码：000935 证券简称：四川双马 公告编号：2025-8 四川和谐双马股份有限公司 关于公司董事、副总经理兼董事会秘书辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四川和谐双马股份有限公司（以下简称"公司"）董事会于 2025 年 3 月 31 日收到公司董事、副总经理兼董事会秘书陈长春先生提交的书面辞职报告，陈长 春先生由于个人原因提请辞去公司董事、副总经理兼董事会秘书的职务，辞职后 不再担任公司及控股子公司的其他职务。 陈长春先生的辞职不会导致公司董事会成员人数低于法定最低人数，不会影 响公司董事会的正常运作及公司经营管理的正常运行。根据《深圳证券交易所上 市公司自律监管指引第 1 号——主板上市公司规范运作》等相关规定，陈长春先 生的辞职报告自送达公司董事会之日起生效。截至本公告披露日，陈长春先生未 持有公司股份，不存在应当履行而未履行的承诺事项。 通讯地址：四川省成都市锦江区红星路三段一号成都国际金融中心 1 号写 字楼 26 楼 2 号 电子邮箱：public.sm@sc-shuangma.com 特此公告。 四川和谐双马股份 ...

Group 1 - The core viewpoint of the article is that Sichuan Shuangma (000935) has invested in a smart mobility fund that includes Xiaopeng Motors, and any increase in Xiaopeng's stock price will positively impact the company's performance [1] - The company acknowledges that the stock price changes of its invested listed companies will affect its financial reports, indicating a level of uncertainty [1]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 22.27 RMB based on a valuation of 170 billion RMB for 2025 [3]. Core Insights - The company is expected to benefit from a favorable technology growth style and an improving exit channel for its private equity business, leading to anticipated earnings elasticity [3]. - The report highlights significant investments in technology sectors, including participation in funds that have invested in leading companies in AI and robotics, which are expected to drive future growth [1][2]. Summary by Sections Investment Projects - The company has invested in Hangzhou Qunhe Information Technology Co., which has submitted a listing application to the Hong Kong Stock Exchange, and in the Fourier project in the robotics industry [1]. - Fourier has completed a new financing round totaling nearly 800 million RMB and provides robotic solutions widely used in medical rehabilitation and academic research [2]. Financial Forecasts - The projected net profits for the company are 3.5 billion RMB in 2024, 6.5 billion RMB in 2025, and 9.5 billion RMB in 2026, reflecting a year-on-year change of -64%, +85%, and +47% respectively [3]. - Revenue is expected to decline to 1.006 billion RMB in 2024 before rebounding to 1.456 billion RMB in 2025 and 1.775 billion RMB in 2026, with growth rates of -17.5%, +44.8%, and +21.9% respectively [6]. Market Performance - The report notes that several investment projects have successfully gone public, with significant stock price increases since 2025, including a 95.9% increase for Aojie Technology and a 60.2% increase for BGI Intelligent Manufacturing [2].

证券代码：000935 证券简称：四川双马 公告编号：2025-7 四川和谐双马股份有限公司 关于控股子公司湖北健翔 获得化学原料药上市申请批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 四川和谐双马股份有限公司（简称"公司"）控股子公司湖北健翔生物制药 有限公司（简称"湖北健翔"）于近期获得国家药品监督管理局核准签发的缩宫 素《化学原料药上市申请批准通知书》。现将相关情况公告如下： 一、本次获得化学原料药上市申请批准通知书的具体情况 1、化学原料药名称 （1）通用名称:缩宫素 （2）英文名/拉丁名:Oxytocin 2、登记号:Y20220001017 6、有效期：24 个月 7、包装规格：200g/听 8、申请事项：境内生产化学原料药上市申请。 9、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执 行。 10、生产企业： （1）名称：湖北健翔生物制药有限公司 （2）地址：湖北咸宁咸安经济开发区绿山路 9 号 3、受理号:CYHS2360428 4、通知书编号: ...

Group 1: Company Overview and Acquisition - Sichuan Harmony Shuangma Co., Ltd. is engaged in industrial investment and management, as well as private equity fund management, with a focus on building materials and private equity investment funds [2] - In 2024, the company completed the acquisition of Shenzhen Jianyuan, expanding its business scope and strategic deployment [2] Group 2: Production Capacity and Market Position - Shenzhen Jianyuan's annual production capacity exceeds 4 tons, with a maximum batch size of 100 kg; specifically, the GLP-1 raw material capacity is 2 tons, with a single batch size reaching 20 kg [3] - The global GLP-1 drug market has grown from $9.3 billion in 2018 to $38.9 billion in 2023, with a compound annual growth rate (CAGR) of 33.2%, projected to reach $98.8 billion by 2028 with a CAGR of 20.5% [5] Group 3: Revenue and Product Segmentation - In 2024, GLP-1 raw materials are expected to account for approximately 70% of Shenzhen Jianyuan's revenue, with major products contributing over 20% and 40% respectively [4] - The company has received orders for oral formulations of semaglutide, with significant sales expected this year [4] Group 4: Strategic Development and Future Plans - The company has plans for capacity expansion in response to market demand for GLP-1 products, with ongoing construction based on market changes [3] - Future growth is anticipated as Shenzhen Jianyuan enters a rapid development phase, leveraging its technological and market advantages [4] Group 5: Investment and Fund Management - As of June 30, 2024, the company generated investment income of 1.654 billion yuan from two funds, with an expected increase in excess performance remuneration as the capital market recovers [4] - The Harmony Green Industry Fund has begun project investments, focusing on high-end manufacturing, artificial intelligence, new energy, and semiconductors [4] Group 6: Corporate Governance and Management Enhancements - Post-acquisition, Sichuan Harmony Shuangma restructured Shenzhen Jianyuan's board and management, enhancing operational efficiency and risk control [5] - The company is committed to establishing a robust internal control system and optimizing management processes to ensure high operational efficiency [5]

Summary of Conference Call Records Company and Industry Involved - The conference call primarily discusses **Shuangma** and its investment strategies, particularly in the **technology** and **new manufacturing** sectors. Key Points and Arguments 1. **Investment Focus**: Shuangma's investment direction continues to focus on technology and new manufacturing, with approximately 10 projects invested in the previous year and plans for more investments as the market environment improves [1] 2. **Fund Management**: The company currently manages three funds, with two nearing the end of their investment periods, having invested in over a hundred projects [1] 3. **Market Conditions**: The capital market has faced challenges in the past two years, but there is optimism for better opportunities in the current year due to government support and policy adjustments [2] 4. **Empowerment of Jianyuan**: Post-acquisition, Shuangma has restructured Jianyuan's board and management, aligning its long-term goals with Shuangma's overall business strategy [3][4] 5. **Management Efficiency**: Efforts have been made to optimize Jianyuan's management efficiency and internal control systems, enhancing its business development and risk management capabilities [4] 6. **Industry Outlook**: The company remains optimistic about the industry’s growth potential, particularly as patents expire, which is expected to drive market growth [5] 7. **Shareholder Actions**: Recent share reductions by two shareholders are attributed to their own funding needs, with minimal expected impact on the company’s market performance [6][7] 8. **Fund Performance**: The performance of funds has been stable, with expectations for a gradual recovery in investment returns as market conditions improve [12][14] 9. **Water Industry Challenges**: The water industry is currently facing losses, but there is hope for recovery due to national infrastructure projects and adjustments in the economy [15] 10. **Investment in AI and Technology**: Shuangma is actively investing in technology sectors, including AI, and plans to continue this focus in future investments [16][17] 11. **Fund Size and Projects**: The total scale of Shuangma's funds is approximately 30 billion, with over 100 companies involved in various projects [18] 12. **Future Expectations**: The company anticipates stable management fee income and potential for significant returns in 2025 as market conditions stabilize [14][18] Other Important but Overlooked Content - The company emphasizes the importance of maintaining a strong internal control system and efficient management processes to ensure high operational efficiency [4] - There is a clear strategy for future investments in biomedicine and life sciences, indicating a shift towards these sectors as new mainstays for growth [16] - Historical investment successes in technology sectors are highlighted as a foundation for future strategies, reinforcing the commitment to investing in companies with technological capabilities [17]

证券代码：000935 证券简称：四川双马 公告编号：2025-6 四川和谐双马股份有限公司 关于控股子公司深圳健元获得欧洲发明专利的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 四川和谐双马股份有限公司（简称"公司"）控股子公司深圳市健元医药科 技有限公司于近期收到了欧洲专利局颁发的发明专利证书。 一、本次取得欧洲发明专利证书的具体情况 1 、 专 利 名 称 ： SYNTHESIS METHOD FOR LOW‑RACEMIZATION IMPURITY LIRAGLUTIDE（低消旋杂质利拉鲁肽的合成方法） 4、专利类型：发明专利 5、申请日期：2017 年 8 月 18 日 6、授权日期：2025 年 1 月 15 日 利拉鲁肽是人胰高血糖素样肽-1（GLP-1）类似物，用于治疗Ⅱ型糖尿病、 体重管理。本专利为合成利拉鲁肽的新工艺，该工艺在确保收率稳定的同时，实 现了与产品性质极为相似的消旋杂质[D‑Thr5 ]-利拉鲁肽的大幅降低，有利于提 升产品的质量。 二、对公司的影响 欧洲是公司重要的海外市场之一，本次欧洲专利的取得是公司研发综合实力 ...